nach oben

Clinical Rheumatology

Erschienen in:

03.02.2020 | Review Article

Obesity and its role in the management of rheumatoid and psoriatic arthritis

verfasst von: Luca Moroni, Nicola Farina, Lorenzo Dagna

Erschienen in: Clinical Rheumatology | Ausgabe 4/2020

Einloggen, um Zugang zu erhalten

Abstract

In the last decade, interest has been growing in the relationship between obesity and several other clinical conditions, besides the well-established links between body mass index (BMI) and cardiovascular diseases or cancer. A particular focus has been put on the impact of a higher BMI on immune-mediated diseases such as rheumatoid arthritis (RA) and psoriatic arthritis (PsA). Obesity has been found to be associated with greater arthritis activity and a reduced probability of response to anti-tumor necrosis factor (TNF) agents. On the other hand, weight loss increases the chances of treatment success. Although the direct effect of a higher body mass on drug clearance might in part account for this obesity-related effect, other biological mechanisms could be involved. The evidence of a negative influence of obesity on arthritis treatment is particularly strong as far as anti-TNF inhibition is concerned; on the contrary, the response to biologic agents targeting interleukin-6, cytotoxic T lymphocyte antigen 4, or CD20 seems not to be negatively affected by a higher BMI. In this review, we will consider the main studies investigating the influence of obesity on anti-rheumatic treatment in RA and PsA patients. We will also try to hypothesize about a possible pathogenic explanation of this phenomenon and its role in the choice of an appropriate and personalized therapy.

Withrow D, Alter DA (2011) The economic burden of obesity worldwide: a systematic review of the direct costs of obesity. Obes Rev 12(2):131–141. https://doi.org/10.1111/j.1467-789X.2009.00712.x CrossRefPubMed

Liu Y, Hazlewood GS, Kaplan GG, Eksteen B, Barnabe C (2017) Impact of obesity on remission and disease activity in rheumatoid arthritis: a systematic review and meta-analysis. Arthritis Care Res 69(2):157–165. https://doi.org/10.1002/acr.22932 CrossRef

Singh JA, Saag KG, Bridges SL Jr, Akl EA, Bannuru RR, Sullivan MC, Vaysbrot E, McNaughton C, Osani M, Shmerling RH, Curtis JR, Furst DE, Parks D, Kavanaugh A, O'Dell J, King C, Leong A, Matteson EL, Schousboe JT, Drevlow B, Ginsberg S, Grober J, St Clair EW, Tindall E, Miller AS, McAlindon T (2016) 2015 American College of Rheumatology Guideline for the treatment of rheumatoid arthritis. Arthritis Rheum 68(1):1–26. https://doi.org/10.1002/art.39480 CrossRef

Passot C, Mulleman D, Bejan-Angoulvant T, Aubourg A, Willot S, Lecomte T, Picon L, Goupille P, Paintaud G, Ternant D (2016) The underlying inflammatory chronic disease influences infliximab pharmacokinetics. mAbs 8(7):1407–1416. https://doi.org/10.1080/19420862.2016.1216741 CrossRefPubMedPubMedCentral

Lumeng CN, Saltiel AR (2011) Inflammatory links between obesity and metabolic disease. J Clin Invest 121(6):2111–2117. https://doi.org/10.1172/JCI57132 CrossRefPubMedPubMedCentral

Galluzzo M, D'Adamio S, Servoli S, Bianchi L, Chimenti S, Talamonti M (2016) Tofacitinib for the treatment of psoriasis. Expert Opin Pharmacother 17(10):1421–1433. https://doi.org/10.1080/14656566.2016.1195812 CrossRefPubMed

Feng J, Chen Q, Yu F, Wang Z, Chen S, Jin Z, Cai Q, Liu Y, He J (2016) Body mass index and risk of rheumatoid arthritis: a meta-analysis of observational studies. Medicine (Baltimore) 95(8):e2859. https://doi.org/10.1097/MD.0000000000002859 CrossRef

Qin B, Yang M, Fu H, Ma N, Wei T, Tang Q, Hu Z, Liang Y, Yang Z, Zhong R (2015) Body mass index and the risk of rheumatoid arthritis: a systematic review and dose-response meta-analysis. Arthritis Res Ther 17:86. https://doi.org/10.1186/s13075-015-0601-x CrossRefPubMedPubMedCentral

Wesley A, Bengtsson C, Elkan AC, Klareskog L, Alfredsson L, Wedren S, Epidemiological Investigation of Rheumatoid Arthritis Study G (2013) Association between body mass index and anti-citrullinated protein antibody-positive and anti-citrullinated protein antibody-negative rheumatoid arthritis: results from a population-based case-control study. Arthritis Care Res 65(1):107–112. https://doi.org/10.1002/acr.21749 CrossRef

10.

Lu B, Hiraki LT, Sparks JA, Malspeis S, Chen CY, Awosogba JA, Arkema EV, Costenbader KH, Karlson EW (2014) Being overweight or obese and risk of developing rheumatoid arthritis among women: a prospective cohort study. Ann Rheum Dis 73(11):1914–1922. https://doi.org/10.1136/annrheumdis-2014-205459 CrossRefPubMedPubMedCentral

11.

Rodriguez LA, Tolosa LB, Ruigomez A, Johansson S, Wallander MA (2009) Rheumatoid arthritis in UK primary care: incidence and prior morbidity. Scand J Rheumatol 38(3):173–177. https://doi.org/10.1080/03009740802448825 CrossRefPubMed

12.

Wolfe F, Mitchell DM, Sibley JT, Fries JF, Bloch DA, Williams CA, Spitz PW, Haga M, Kleinheksel SM, Cathey MA (1994) The mortality of rheumatoid arthritis. Arthritis Rheum 37(4):481–494. https://doi.org/10.1002/art.1780370408 CrossRefPubMed

13.

Escalante A, Haas RW, del Rincon I (2005) Paradoxical effect of body mass index on survival in rheumatoid arthritis: role of comorbidity and systemic inflammation. Arch Intern Med 165(14):1624–1629. https://doi.org/10.1001/archinte.165.14.1624 CrossRefPubMed

14.

van der Helm-van Mil AH, van der Kooij SM, Allaart CF, Toes RE, Huizinga TW (2008) A high body mass index has a protective effect on the amount of joint destruction in small joints in early rheumatoid arthritis. Ann Rheum Dis 67(6):769–774. https://doi.org/10.1136/ard.2007.078832 CrossRef

15.

Vidal C, Barnetche T, Morel J, Combe B, Daien C (2015) Association of body mass index categories with disease activity and radiographic joint damage in rheumatoid arthritis: a systematic review and metaanalysis. J Rheumatol 42(12):2261–2269. https://doi.org/10.3899/jrheum.150224 CrossRefPubMed

16.

Ellerby N, Mattey DL, Packham J, Dawes P, Hider SL (2014) Obesity and comorbidity are independently associated with a failure to achieve remission in patients with established rheumatoid arthritis. Ann Rheum Dis 73(11):e74. https://doi.org/10.1136/annrheumdis-2014-206254 CrossRefPubMed

17.

Sandberg ME, Bengtsson C, Kallberg H, Wesley A, Klareskog L, Alfredsson L, Saevarsdottir S (2014) Overweight decreases the chance of achieving good response and low disease activity in early rheumatoid arthritis. Ann Rheum Dis 73(11):2029–2033. https://doi.org/10.1136/annrheumdis-2013-205094 CrossRefPubMed

18.

Schulman E, Bartlett SJ, Schieir O, Andersen KM, Boire G, Pope JE, Hitchon C, Jamal S, Thorne JC, Tin D, Keystone EC, Haraoui B, Goodman SM, Bykerk VP, Investigators C (2018) Overweight, obesity, and the likelihood of achieving sustained remission in early rheumatoid arthritis: results from a multicenter prospective cohort study. Arthritis Care Res 70(8):1185–1191. https://doi.org/10.1002/acr.23457 CrossRef

19.

Ajeganova S, Andersson ML, Hafstrom I, Group BS (2013) Association of obesity with worse disease severity in rheumatoid arthritis as well as with comorbidities: a long-term followup from disease onset. Arthritis Care Res 65(1):78–87. https://doi.org/10.1002/acr.21710 CrossRef

20.

Kaeley GS, MacCarter DK, Pangan AL, Wang X, Kalabic J, Ranganath VK (2018) Clinical responses and synovial vascularity in obese rheumatoid arthritis patients treated with adalimumab and methotrexate. J Rheumatol 45(12):1628–1635. https://doi.org/10.3899/jrheum.171232 CrossRefPubMed

21.

Kim SK, Choe JY, Park SH, Lee H (2016) No predictive effect of body mass index on clinical response in patients with rheumatoid arthritis after 24 weeks of biological disease-modifying antirheumatic drugs: a single-center study. Clin Rheumatol 35(5):1129–1136. https://doi.org/10.1007/s10067-016-3220-2 CrossRefPubMed

22.

Klaasen R, Wijbrandts CA, Gerlag DM, Tak PP (2011) Body mass index and clinical response to infliximab in rheumatoid arthritis. Arthritis Rheum 63(2):359–364. https://doi.org/10.1002/art.30136 CrossRefPubMed

23.

Ottaviani S, Gardette A, Tubach F, Roy C, Palazzo E, Gill G, Meyer O, Dieude P (2015) Body mass index and response to infliximab in rheumatoid arthritis. Clin Exp Rheumatol 33(4):478–483PubMed

24.

Ottaviani S, Gardette A, Roy C, Tubach F, Gill G, Palazzo E, Meyer O, Dieude P (2015) Body mass index and response to rituximab in rheumatoid arthritis. Joint Bone Spine 82(6):432–436. https://doi.org/10.1016/j.jbspin.2015.02.011 CrossRefPubMed

25.

Gardette A, Ottaviani S, Sellam J, Berenbaum F, Liote F, Meyer A, Sibilia J, Fautrel B, Palazzo E, Dieude P (2016) Body mass index and response to tocilizumab in rheumatoid arthritis: a real life study. Clin Rheumatol 35(4):857–861. https://doi.org/10.1007/s10067-016-3183-3 CrossRefPubMed

26.

Pers YM, Godfrin-Valnet M, Lambert J, Fortunet C, Constant E, Mura T, Pallot-Prades B, Jorgensen C, Maillefert JF, Marotte H, Wendling D, Gaudin P (2015) Response to tocilizumab in rheumatoid arthritis is not influenced by the body mass index of the patient. J Rheumatol 42(4):580–584. https://doi.org/10.3899/jrheum.140673 CrossRefPubMed

27.

Kivitz A, Olech E, Borofsky M, Zazueta BM, Navarro-Sarabia F, Radominski SC, Merrill JT, Rowell L, Nasmyth-Miller C, Bao M, Wright S, Pope JE (2014) Subcutaneous tocilizumab versus placebo in combination with disease-modifying antirheumatic drugs in patients with rheumatoid arthritis. Arthritis Care Res 66(11):1653–1661. https://doi.org/10.1002/acr.22384 CrossRef

28.

Gardette A, Ottaviani S, Sellam J, Berenbaum F, Liote F, Fautrel B, Palazzo E, Meyer A, Sibilia J, Dieude P (2016) Body mass index and response to abatacept in rheumatoid arthritis. Eur J Clin Investig 46(12):1048–1052. https://doi.org/10.1111/eci.12691 CrossRef

29.

Mariette X, Alten R, Nusslein HG, Galeazzi M, Lorenz HM, Cantagrel A, Chartier M, Poncet C, Rauch C, Le Bars M (2017) The effect of body mass index on clinical response to abatacept as a first-line biologic for rheumatoid arthritis: 6-month results from the 2-year, observational, prospective ACTION study. Joint Bone Spine 84(5):571–576. https://doi.org/10.1016/j.jbspin.2016.10.011 CrossRefPubMed

30.

D'Agostino MA, Alten R, Mysler E, Le Bars M, Ye J, Murthy B, Heitzmann J, Vadanici R, Ferraccioli G (2017) Body mass index and clinical response to intravenous or subcutaneous abatacept in patients with rheumatoid arthritis. Clin Rheumatol 36(12):2655–2665. https://doi.org/10.1007/s10067-017-3788-1 CrossRefPubMedPubMedCentral

31.

Iannone F, Courvoisier DS, Gottenberg JE, Hernandez MV, Lie E, Canhao H, Pavelka K, Hetland ML, Turesson C, Mariette X, Choquette D, Finckh A (2017) Body mass does not impact the clinical response to intravenous abatacept in patients with rheumatoid arthritis. Analysis from the “pan-European registry collaboration for abatacept (PANABA). Clin Rheumatol 36 (4):773–779. doi:https://doi.org/10.1007/s10067-016-3505-5

32.

Kaushik SB, Lebwohl MG (2019) Psoriasis: which therapy for which patient: psoriasis comorbidities and preferred systemic agents. J Am Acad Dermatol 80(1):27–40. https://doi.org/10.1016/j.jaad.2018.06.057 CrossRefPubMed

33.

Paul C, Cather J, Gooderham M, Poulin Y, Mrowietz U, Ferrandiz C, Crowley J, Hu C, Stevens RM, Shah K, Day RM, Girolomoni G, Gottlieb AB (2015) Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2). Br J Dermatol 173(6):1387–1399. https://doi.org/10.1111/bjd.14164 CrossRefPubMed

34.

Bardazzi F, Balestri R, Baldi E, Antonucci A, De Tommaso S, Patrizi A (2010) Correlation between BMI and PASI in patients affected by moderate to severe psoriasis undergoing biological therapy. Dermatol Ther 23(Suppl 1):S14–S19. https://doi.org/10.1111/j.1529-8019.2009.01281.x CrossRefPubMed

35.

Zhu Y, Hu C, Lu M, Liao S, Marini JC, Yohrling J, Yeilding N, Davis HM, Zhou H (2009) Population pharmacokinetic modeling of ustekinumab, a human monoclonal antibody targeting IL-12/23p40, in patients with moderate to severe plaque psoriasis. J Clin Pharmacol 49(2):162–175. https://doi.org/10.1177/0091270008329556 CrossRefPubMed

36.

Papp KA, Reich K, Paul C, Blauvelt A, Baran W, Bolduc C, Toth D, Langley RG, Cather J, Gottlieb AB, Thaci D, Krueger JG, Russell CB, Milmont CE, Li J, Klekotka PA, Kricorian G, Nirula A (2016) A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis. Br J Dermatol 175(2):273–286. https://doi.org/10.1111/bjd.14493 CrossRefPubMed

37.

Reich K, Puig L, Mallbris L, Zhang L, Osuntokun O, Leonardi C (2017) The effect of bodyweight on the efficacy and safety of ixekizumab: results from an integrated database of three randomised, controlled phase 3 studies of patients with moderate-to-severe plaque psoriasis. J Eur Acad Dermatol Venereol 31(7):1196–1207. https://doi.org/10.1111/jdv.14252 CrossRefPubMed

38.

di Minno MN, Peluso R, Iervolino S, Lupoli R, Russolillo A, Scarpa R, di Minno G (2013) Obesity and the prediction of minimal disease activity: a prospective study in psoriatic arthritis. Arthritis Care Res 65(1):141–147. https://doi.org/10.1002/acr.21711 CrossRef

39.

Costa L, Caso F, Ramonda R, Del Puente A, Cantarini L, Darda MA, Caso P, Lorenzin M, Fiocco U, Punzi L, Scarpa R (2015) Metabolic syndrome and its relationship with the achievement of minimal disease activity state in psoriatic arthritis patients: an observational study. Immunol Res 61(1–2):147–153. https://doi.org/10.1007/s12026-014-8595-z CrossRefPubMed

40.

Eder L, Thavaneswaran A, Chandran V, Cook RJ, Gladman DD (2015) Obesity is associated with a lower probability of achieving sustained minimal disease activity state among patients with psoriatic arthritis. Ann Rheum Dis 74(5):813–817. https://doi.org/10.1136/annrheumdis-2013-204448 CrossRefPubMed

41.

Hojgaard P, Glintborg B, Kristensen LE, Gudbjornsson B, Love TJ, Dreyer L (2016) The influence of obesity on response to tumour necrosis factor-alpha inhibitors in psoriatic arthritis: results from the DANBIO and ICEBIO registries. Rheumatology 55(12):2191–2199. https://doi.org/10.1093/rheumatology/kew326 CrossRefPubMed

42.

Ogdie A, Palmer JL, Greenberg J, Curtis JR, Harrold LR, Solomon DH, Kavanaugh A, Kremer JM, Mease PJ (2019) Predictors of achieving remission among patients with psoriatic arthritis initiating a tumor necrosis factor inhibitor. J Rheumatol. https://doi.org/10.3899/jrheum.171034

43.

Mease PJ, Gottlieb AB, van der Heijde D, FitzGerald O, Johnsen A, Nys M, Banerjee S, Gladman DD (2017) Efficacy and safety of abatacept, a T-cell modulator, in a randomised, double-blind, placebo-controlled, phase III study in psoriatic arthritis. Ann Rheum Dis 76(9):1550–1558. https://doi.org/10.1136/annrheumdis-2016-210724 CrossRefPubMedPubMedCentral

44.

McInnes IB, Ferraccioli G, D'Agostino MA, Le Bars M, Banerjee S, Ahmad HA, Elbez Y, Mease PJ (2019) Body mass index and treatment response to subcutaneous abatacept in patients with psoriatic arthritis: a post hoc analysis of a phase III trial. RMD Open 5(1):e000934. https://doi.org/10.1136/rmdopen-2019-000934 CrossRefPubMedPubMedCentral

45.

Rheinheimer J, de Souza BM, Cardoso NS, Bauer AC, Crispim D (2017) Current role of the NLRP3 inflammasome on obesity and insulin resistance: a systematic review. Metabolism 74:1–9. https://doi.org/10.1016/j.metabol.2017.06.002 CrossRefPubMed

46.

Mastrocola R, Aragno M, Alloatti G, Collino M, Penna C, Pagliaro P (2018) Metaflammation: tissue-specific alterations of the NLRP3 inflammasome platform in metabolic syndrome. Curr Med Chem 25(11):1294–1310. https://doi.org/10.2174/0929867324666170407123522 CrossRefPubMed

47.

Medina G, Vera-Lastra O, Peralta-Amaro AL, Jimenez-Arellano MP, Saavedra MA, Cruz-Dominguez MP, Jara LJ (2018) Metabolic syndrome, autoimmunity and rheumatic diseases. Pharmacol Res 133:277–288. https://doi.org/10.1016/j.phrs.2018.01.009 CrossRefPubMed

48.

Singh S, Facciorusso A, Singh AG, Vande Casteele N, Zarrinpar A, Prokop LJ, Grunvald EL, Curtis JR, Sandborn WJ (2018) Obesity and response to anti-tumor necrosis factor-alpha agents in patients with select immune-mediated inflammatory diseases: a systematic review and meta-analysis. PLoS One 13(5):e0195123. https://doi.org/10.1371/journal.pone.0195123 CrossRefPubMedPubMedCentral

49.

Agca R, Heslinga SC, Rollefstad S, Heslinga M, McInnes IB, Peters MJ, Kvien TK, Dougados M, Radner H, Atzeni F, Primdahl J, Sodergren A, Wallberg Jonsson S, van Rompay J, Zabalan C, Pedersen TR, Jacobsson L, de Vlam K, Gonzalez-Gay MA, Semb AG, Kitas GD, Smulders YM, Szekanecz Z, Sattar N, Symmons DP, Nurmohamed MT (2017) EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update. Ann Rheum Dis 76(1):17–28. https://doi.org/10.1136/annrheumdis-2016-209775 CrossRefPubMed

50.

Shan J, Zhang J (2019) Impact of obesity on the efficacy of different biologic agents in inflammatory diseases: a systematic review and meta-analysis. Joint Bone Spine 86(2):173–183. https://doi.org/10.1016/j.jbspin.2018.03.007 CrossRefPubMed

Titel: Obesity and its role in the management of rheumatoid and psoriatic arthritis
verfasst von: Luca Moroni
Nicola Farina
Lorenzo Dagna
Publikationsdatum: 03.02.2020
Verlag: Springer London
Erschienen in: Clinical Rheumatology / Ausgabe 4/2020
Print ISSN: 0770-3198
Elektronische ISSN: 1434-9949
DOI: https://doi.org/10.1007/s10067-020-04963-2

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

25.04.2024 | Hypotonie | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Obesity and its role in the management of rheumatoid and psoriatic arthritis

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Update Innere Medizin

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2020

A retrospective study of bone scintigraphy in the follow-up of patients with synovitis, acne, pustulosis, hyperostosis, and osteitis syndrome: is it useful to repeat bone scintigraphy for disease assessment?

Prevalence of musculoskeletal complaints in urban communities in multi-ethnic Suriname: a cross-sectional study with the COPCORD methodology (stage 1, phase 1 and 2)

Correction to: The association between anxiety and disease activity and quality of life in rheumatoid arthritis: a systematic review and meta-analysis

Disease activity–based management of rheumatoid arthritis in Dutch daily clinical practice has improved over the past decade

MRI compared with low-dose CT scanning in the diagnosis of axial spondyloarthritis

The knowledge level of rheumatoid arthritis patients about their disease in a developing country. A study in 168 Bangladeshi RA patients

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Update Innere Medizin